All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F13%3A00058800" target="_blank" >RIV/00023001:_____/13:00058800 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064173:_____/13:N0000013

  • Result on the web

    <a href="http://jama.jamanetwork.com/article.aspx?articleid=1666394" target="_blank" >http://jama.jamanetwork.com/article.aspx?articleid=1666394</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1001/jama.2013.1954" target="_blank" >10.1001/jama.2013.1954</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial

  • Original language description

    IMPORTANCE:Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality. OBJECTIVE: To investigate whether aliskiren, a direct renin inhibitor, when added to standard therapy, would reduce the rate of cardiovascular (CV) death or HF rehospitalization among HHF patients. INTERVENTION: All patients received 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months. MAIN OUTCOME MEASURES Cardiovascular death or HF rehospitalization at 6 months and 12 months. RESULTS: In total, 1639 patients were randomized, with 1615 patients included in the final efficacyanalysis cohort (808 aliskiren, 807 placebo). Mean age was 65 years; mean LVEF, 28%; 41% of patients had diabetes mellitus, mean estimated glomerular filtration rate, 67 mL/min/1.73 m2. At admission and randomization, median NT-proBNP lev

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    JAMA

  • ISSN

    0098-7484

  • e-ISSN

  • Volume of the periodical

    309

  • Issue of the periodical within the volume

    11

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    11

  • Pages from-to

    1125-1135

  • UT code for WoS article

    000316276500026

  • EID of the result in the Scopus database